its understanding of factors affecting the pathogenesis, development, and progression of fibrotic lung disease. We have also heralded the availability of two new medications for the treatment of idiopathic pulmonary fibrosis (IPF) (1, 2) . However, more work is clearly needed to further our understanding of mechanisms of fibrogenesis and to enhance the translatability of scientific discoveries. Recently, the NHLBI convened a workshop to define priorities in specific areas of IPF research (3); similarly, a working group of the Respiratory Cell and Molecular Biology (RCMB) Assembly of the American Thoracic Society (ATS) convened a workshop to discuss comparative pathobiology of lung fibrosis between humans and domestic animals (4) as well as a conference to plan biorepository strategies among academic institutions, industry partners, patient advocacy groups, and government agencies (5) . Complementary to these works, we convened an ad hoc subcommittee from the RCMB Working Group on Lung Fibrosis, composed of investigators with experience in bench-based, translational, and patient-based pulmonary fibrosis research, to enumerate and elaborate on conceptual priorities in pulmonary fibrosis research.
Our group initially met at the ATS International Conference in San Diego (May, 2014) to discuss prior research successes and current roadblocks to further progress. A second meeting was held at the International Colloquium on Lung and Airway Fibrosis in Mont Tremblant, Quebec, Canada (September, 2014), at which time subgroups were formed and tasked with researching and writing various sections of the document. The draft document was reviewed and edited by all members of the group. A third meeting at the ATS International Conference in Denver (May, 2015) was held to finalize the document. As a result of these meetings, the group identified the following major challenges:
d Current in vivo, in vitro, ex vivo, and in silico models of human lung fibrosis have been instrumental to our understanding of lung fibrogenesis but largely do not resemble human disease. This may be due to anatomic, age and/or functional differences among species and models, artificiality/ duration of the initial fibrotic insult, nonphysiologic culture conditions, or lack of standardized endpoints, to name a few. d Funding for pulmonary fibrosis research has been limited to traditional funding sources (e.g., government, advocacy groups, and industry support). Moving forward, these sources are likely to be insufficient to sustain the research endeavors necessary to drive the field forward. d The infrastructure needed to conduct high-quality, patient-relevant research in fibrotic lung disease is suboptimal.
Although individual researchers and centers may have access to patientrelated materials and data, these samples are often unavailable to large portions of the scientific community, thereby hampering scientific progress. Additionally, quality of both data and matching samples may be limiting. d Timely clinical study of potential therapeutics or diagnostics identified in preclinical research is hampered by difficulties faced by researchers in engaging centers with expertise in clinical study design and execution. d Pulmonary fibrosis is rare and daunting to address for both patient and clinician. Despite the worldwide increasing incidence in lung fibrosis (and fibrosis of other organ systems) (6), a global approach to lung fibrosis research is lacking.
To confront these challenges, the group made the following recommendations: 
Introduction
Pulmonary fibrosis is defined as a chronic, frequently progressive, fibrosing interstitial lung disease (ILD) with few effective therapeutic options. Pulmonary fibrosis may occur as a result of occupational exposures (e.g., silica, beryllium), drug toxicity (e.g., methotrexate, amiodarone, nitrofurantoin), and connective tissue diseases (e.g., scleroderma), or it may be idiopathic in etiology (e.g., IPF). The incidence of IPF and other fibrotic disorders of lung is on the rise worldwide, likely affecting hundreds of thousands, or even millions, of patients globally (7) . Although research efforts to date in the bench-based and clinicbased arenas have yielded much important information regarding potential etiologies, pathogenesis, natural history, and diagnostic approaches of various fibrotic lung diseases, there has not been a commensurate increase in therapeutic options or survival of these patients. Despite the approval by the U.S. Food and Drug Administration in October, 2014 of both pirfenidone and nintedanib for patients with IPF, no drug has conclusively been shown to improve survival or quality of life in patients with fibrotic lung disorders, despite a slowing of the rate of decline in FVC, leaving lung transplantation (which is limited to a minority of patients) as the only potentially life-prolonging treatment option (8) .
Recently, the NHLBI convened a workshop to outline scientific topics that require further study in IPF, resulting in a workshop report enumerating specific scientific priorities (3). Related but separate reports focusing on fibrosis across various organ systems (G.P. Cosgrove and colleagues, unpublished material) and AMERICAN THORACIC SOCIETY DOCUMENTS pulmonary fibrosis across species (G. Vicary and colleagues, unpublished results) are currently being prepared. All reports define priority areas of scientific investigation in patients with IPF (although these priorities could be extended to all fibrotic lung diseases) but do not describe the means by which this research will proceed successfully. Thus, an ad hoc group of investigators with experience in bench-based, translational, and patient-based research was convened to identify strengths and challenges in performing pulmonary fibrosis research and to offer specific suggestions for enhancing future research endeavors in pulmonary fibrosis. This Research Statement will provide a forward-looking framework we believe to be critical to the advancement of lung fibrosis research, centered around five pillars: modeling lung fibrosis, engaging stakeholders, infrastructure development, establishing synergistic relationships between clinical and preclinical networks, and development of a global lung fibrosis initiative.
Methods
The project was initiated as an RCMB Assembly Project and approved by the ATS Project Review Subcommittee. Participants were each chosen by the Project Chair (E.S.W.) because of expertise in specific aspects of lung fibrosis research, program development, involvement with patient advocacy groups, and standing in the field. All participants were approved by the RCMB Planning Committee, the RCMB Executive Committee, and the ATS Project Review Subcommittee. International members were chosen to ensure a diverse representation.
The group initially met at the ATS International Conference in San Diego (May, 2014) to discuss prior research successes and current roadblocks to further progress. A second meeting was held at the International Colloquium on Lung and Airway Fibrosis in Mont Tremblant, Quebec (September, 2014), at which time subgroups were formed and tasked with researching and writing various sections of the document. The draft document was reviewed and edited by all members of the group. A final meeting at the ATS International Conference in Denver (May, 2015) was held to finalize the document.
Literature searches were conducted by several group members using traditional biomedical search engines and formal and informal discussions among thought leaders in pulmonary fibrosis research, including bench and clinical investigative academicians in the United States and abroad, patient advocacy representatives, representatives from funding agencies, and pharmaceutical representatives, were undertaken. Recommendations were formulated, and differences were resolved by discussion and iterative consensus (Table 1) .
Potential conflicts of interest were disclosed and vetted in accordance with the policies and procedures of the ATS. The ATS has analyzed this document and its authors' financial disclosures for commercial bias. Several authors have research support or other involvement with industry relevant to lung fibrosis research. The authors have recommended increased industry support of academic lung fibrosis research in general. The ATS views this recommendation and all other recommendations within as appropriate and necessary.
Modeling Lung Fibrosis
Models of lung fibrosis use in vitro, ex vivo, in silico, and in vivo approaches. The group recognizes that although all fibrosis models have scientific value, no single model currently recapitulates all salient features of human disease. Multiple models should be used routinely when testing hypotheses regarding disease pathogenesis or treatment approaches, with the choice of model dependent on the scientific question being posed. This should be accomplished within a "preclinical research network" of centers that rapidly and reliably test putative interventions in a wide variety of complementary models simultaneously (e.g., in vivo animal model, ex vivo lung slice, in vitro cell assays) challenged with various insults appropriate to the scientific question being asked (e.g., bleomycin, silica, radiation, or virus-induced fibrosis). Features of rodent and other animal models of lung fibrosis vary depending on the insult, timing, and strain of animal (reviewed in References 4, 9-11). In this fashion, drugs or other interventions shown to be efficacious in multiple models could be candidates to be tested in a "clinical research network" (CRN) (see ESTABLISHING SYNERGISTIC RELATIONSHIPS BETWEEN CLINICAL AND PRECLINICAL NETWORKS). Moving forward, however, emphasis should also be placed on creating more biologically relevant models of human lung fibrosis.
The ideal model of human lung fibrosis will be characterized by multiple features: it will be clinically relevant to human anatomy and physiology; it will replicate salient aspects of human disease with regard to initiation, pathology (e.g., fibroblastic foci and microscopic honeycombing in the case of usual interstitial pneumonia), disease 
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progression, and age of onset and sex preference; it will allow assessment of contributions from and interactions among various different cell types (including epithelium, fibroblasts, inflammatory cells and endothelial cells) and via various molecular pathways; it will allow testing of reversibility of fibrosis, preferably in the form of a high-throughput screen; it will incorporate cofactors such as environmentally relevant exposures, workrelated factors, and the microbiome, which are not considered with current specific pathogen-free models; it should be widely accessible to researchers worldwide; it should be relatively simple to incorporate into current research endeavors; and it should be relatively inexpensive. Experimental evidence suggests that multiple molecular pathways can lead to the development of lung fibrosis; thus, modeling should also seek to explore the pleiotropic nature of fibrogenesis. To that end, models that are capable of investigating multiple biologic processes simultaneously are more likely to provide insights into human disease pathogenesis. Such a "multiple hit" hypothesis has been forwarded for many ILDs, such as hypersensitivity pneumonitis (12) , sarcoidosis (13) , and IPF (14) . Determining whether this hypothesis is true will require models that take multiple genetic, environmental, and host immunological aberrations into account.
We acknowledge that these are lofty goals that will require significant resources to develop, and we agree that initial iterations of the models will possess only a subset of these qualities. However, the group also feels strongly that the overall cost of developing such models will be recouped many times over by avoiding the expense associated with performing large clinical trials based on current modeling strategies. If the models provide valid, reproducible, and clinically relevant insights into human lung fibrosis, one can envision answering important ongoing questions in human lung fibrosis, such as identifying triggers that initiate fibrosis versus those that exacerbate fibrosis, understanding how normal resolution of lung injury differs from fibrotic resolution, and testing new therapeutic options. We, therefore, recommend: 
Engaging Stakeholders to Identify Novel Sources of Research Funding
Large investments have been made directed at improving understanding of lung fibrogenesis through exploration of cellular pathways of inflammation, fibroproliferation, and tissue remodeling; characterization and study of animal models of lung fibrosis; and investigation of treatments in clinical trials. Despite this investment, the incidence of fibrotic lung diseases continues to increase (15) (16) (17) , total healthcare expenditures for patients with pulmonary fibrosis are high (18, 19) , hospitalization rates appear to be increasing (20, 21) , and mortality rates remain elevated in both sexes (8) . Lung transplantation, considered the most effective treatment for end-stage fibrotic lung disease, is not without complications and is only available to a minority of patients. Recently approved drugs are suboptimal (1, 2), necessitating further research aimed at not only halting progression or reversing fibrosis but also primary prevention. Indeed, the NHLBI has recently launched an initiative addressing this very issue (22) , and for the vast majority of occupational ILDs, primary prevention may ultimately be the most effective intervention. Regardless of the approaches taken, it is safe to conclude that the human and economic burden of fibrotic lung disease will continue to rise worldwide for decades to come unless we redouble our efforts directed at defining its etiology, elucidating mechanisms involved in its development and progression, and unveiling safe and effective treatments capable of improving quality of life and survival. Any advancement in this area is likely to be applicable to fibrosing conditions of other organs. Over the past 3 decades, the cost of pulmonary fibrosis research has likely reached billions of dollars; some estimates place National Institutes of Health (NIH) expenditures in this area at tens of millions of dollars annually. Yet considering the gaps in knowledge that remain and the continuing burden of pulmonary fibrosis worldwide, we must sustain (if not increase) this effort. Competing (and worthy) research related to other more prevalent lung disorders and other diseases further dilute current resources for research funding. Nevertheless, it is imperative that we continue to work toward raising awareness about pulmonary fibrosis, identifying alternative sources for research funding, and, ultimately, developing a united front to provide "a face" to this condition for potential stakeholders. The following recommendations address these areas: Other potential sources include investment by insurers (both private and public) interested in improving the care of patients they serve or by industry groups with whom lung fibrosis is associated (e.g., coal, tobacco, foundry, etc.), funding research designed to identify best practices that improve quality of life and provide value care. Finally, partnerships among academia, foundations, and the pharmaceutical industry remain important and should be strengthened.
Infrastructure
The field of pulmonary fibrosis research has benefited from a tremendous increase in the number of treatment trials, cohort studies, and available datasets over the last decade; however, many questions remain unanswered. The best quality datasets usually arise from multicenter, prospective, randomized clinical trials. Truly enhancing clinical research in pulmonary fibrosis will require a substantial infrastructure that identifies patients, organizes research protocols, and collects data and biomaterials in a standardized, protocol-driven way. Ultimately, this approach will allow the application of precision medicine approaches to treat patients with lung fibrosis. However, the infrastructure necessary to accomplish this in a coordinated fashion-the institutions that will register patients into databases/ registries, development of standardized protocols for acquisition of samples and clinical data, the physical space to collect and store biological samples, the personnel needed to collect and input longitudinal clinical data-is nonexistent (5 clinical and exposure data, frequency with which it is collected, and protocols for obtaining such data will need to be achieved. Informed consent documents for clinical trials moving forward must be aligned with both the purpose of the clinical study and the biorepository, including specific consent for genetic studies. Careful attention to protection of patient confidentiality will be of the utmost importance.
Establishing Synergistic Relationships between Clinical and Preclinical Networks
The research infrastructure described earlier, although central to future studies in pulmonary fibrosis, would be incomplete without a link to a robust CRN, a consortium of clinical centers and other stakeholders dedicated to the design and conduct of patient-centered research. As first demonstrated by the NHLBI-sponsored IPFnet (Idiopathic Pulmonary Fibrosis Network) (23, 24) , a precursor network that focused primarily on the design and conduct of late-phase clinical trials, collaborative research efforts in fibrotic lung diseases can be highly effective in bringing investigators together and fostering scientific discovery. Such an approach would allow the development of standardized methodological collection of longitudinal clinical and biological data collection, centralized data management across multiple centers, provision of a collaborative clinical center network for efficient implementation of earlyand late-phase clinical trials, creation of a governance structure that promotes merit-based prioritization of resources and protocols, and promotion of standard of care practices to clinicians on the basis of evidence generated from comparative effectiveness and other outcomes research as alluded to in the prior section. A centralized approach to clinical research would allow for standardization and prioritization of patient-based research activities leading to increased efficiency and economy of effort (including identifying optimal trial endpoints, markers of disease progression, and patient-reported outcome instruments). A centralized registry and biorepository would provide a global resource for scientists and allow comparisons across studies that are currently impossible. As more sponsors develop protocols to test novel compounds, and as trials move from placebo controlled to those including approved therapies with larger sample sizes, it will be essential to organize the clinical trial activities of the lung fibrosis community to efficiently identify and enroll patients in the most promising studies. Moreover, this entity would be tasked with identifying optimal design strategies and endpoints in clinical trials to improve efficiency. Although the cost is significant, the need for a large, multicenter CRN may be greater now than it was before the availability of approved therapies. A network of centers with a common interest and experience in clinical research could bring together in partnership patients, clinicians, researchers, advocacy organizations, governmental agencies, and the pharmaceutical industry to provide a stable and strong foundation for future advances. We therefore recommend:
d Assembling a true ILD CRN that will link invested centers together for purposes of clinical research and synergize with preclinical investigators for participation in both bench-tobedside and bedside-to-bench research.
Assembly of such a network will be complex; prospectively defined entry criteria, conflict-resolution strategies, and information dissemination practices will need careful consideration. The above observations emphasize the need to coordinate patients with lung fibrosis and research on a multinational scale. Considering the global impact of this condition, the recognition that multinational clinical trials are needed to test new treatment strategies effectively, and the understanding that "big science" and "big data analysis" are more optimally conducted through large cooperative investigative (preferably international) networks, the need to develop a more organized, concerted global effort targeting pulmonary fibrosis now seems imperative. We recognize that differences in legislation across countries with respect to personal data management are major obstacles to moving this forward; politicians and other lawmakers around the world should be made aware of the need for less restrictive sharing of data while simultaneously strengthening patient protections for personal health information.
A global lung fibrosis initiative should follow the lead of more prevalent pulmonary conditions, such as the GOLD (Global Initiative for Chronic Obstructive Lung Disease) in chronic obstructive pulmonary disease (26) and the GINA (Global Initiative on Asthma) (27) , although we recognize that the initial focus may be slightly different given the relative paucity of treatment options in fibrotic lung disease and the lack of standardized treatment approaches. The group recommends: Rare disease communities, such as pulmonary arterial hypertension, have benefited greatly from global efforts (e.g., the World Health Organization World Symposium on Pulmonary Hypertension [28] ); it is a reasonable expectation that the lung fibrosis community will see similar benefits. Additional benefit will come from the coordinated effort of patient advocacy groups and healthcare professionals to educate the public about the dangers of lung fibrosis, its impact on overall health, and the need for further research in this arena.
We envision a global lung fibrosis initiative that will serve as the umbrella entity for worldwide efforts in: (1) developing a pulmonary fibrosis patient registry and identifying at risk cohorts, (2) creating a data and tissue biorepository, (3) fostering a disease modeling and stratification network, (4) building a clinical trials network, (5) enhancing patient care and research advocacy efforts, and (6) cultivating a global education/outreach program (endorsed by the World Health Organization and international advocacy groups) to educate patients, families, and clinicians about the need for further lung fibrosis research. The message needs to emphasize the purpose of our mission of eradicating fibrotic lung disease: one world, one goal.
The governing structure of a global lung fibrosis initiative may take many forms (one example is seen in Figure 1 ) and would be composed of representatives from each of the major stakeholders in pulmonary fibrosis research and clinical care as described within this document. This structure will be necessary for facilitating decision making, prioritizing the agenda, determining allocation of resources, and coordinating interactions with partners.
Summary
Much progress has been made in the field of pulmonary fibrosis research and clinical care. But like all good research, this progress has raised more questions; prior efforts have been undertaken to identify gaps in our knowledge about lung fibrosis both clinically and scientifically (3) . Logistically, succeeding in moving forward will require securing adequate funding from multiple traditional and newer sources to support the development of newer models of human lung fibrosis, the clinical and preclinical infrastructure to support efficient translation of promising molecules from the bench to the clinic, further epidemiologic studies to define modifiable risk factors, and the education and outreach efforts needed to enhance global awareness of pulmonary fibrosis. This is an ambitious agenda, but we believe it is vital to make the necessary steps forward for patients and their families. n Figure 1 . Example of a governing schematic for a global lung fibrosis initiative. Input from patient representatives, an advisory board, and a governing board would provide overall direction and administration of the initiative to harmonize the goals of addressing the various aspects of lung fibrosis research. Other governance structures may be suitable to achieve the same goal.
